Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 7/20 | 0.45 |
| ▸ | NPY4R | P50391 | 7/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.45 |
| ▸ | NPY1R | P25929 | 5/20 | 0.45 |
| ▸ | GLP1R | P43220 | 6/20 | 0.44 |
| ▸ | GIPR | P48546 | 6/20 | 0.44 |
| ▸ | TFPI | P10646 | 4/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22018329 | 0.98 | NPY2R (0.47) | NPY2RNPY4RNPY5RNPY1RGLP1R | |
| SCHEMBL22380728 | 0.96 | APLNR (0.44) | NPY2RNPY4RNPY5RNPY1RGLP1R | |
| SCHEMBL22380831 | 0.96 | APLNR (0.42) | NPY2RNPY4RNPY5RNPY1RGLP1R | |
| SCHEMBL22018604 | 0.95 | APLNR (0.45) | NPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL22922809 | 0.95 | NPY2R (0.46) | NPY2RNPY4RNPY5RNPY1RGLP1R | |
| SCHEMBL22019191 | 0.95 | NPY2R (0.46) | NPY2RNPY4RNPY5RNPY1RGLP1R | |
| SCHEMBL22922932 | 0.95 | APLNR (0.46) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL22018477 | 0.95 | APLNR (0.46) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL22018361 | 0.95 | APLNR (0.46) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL22018501 | 0.94 | APLNR (0.44) | NPY2RNPY4RNPY5RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037415-B2 | Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient | YUYU PHARMA, INC. (KR) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037415-B2 | Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient | VIP, IAPP, NGLY1 | NPY2R 435/4885NPY4R 762/4885NPY5R 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.